Columbia University researchers identify Alzheimer's protection mechanism

Researchers at Columbia University have identified a biological mechanism that may explain why some individuals carrying the high-risk APOE ε4 gene do not develop Alzheimer’s disease. A study published in Nature Aging suggests that a rare mutation in the fibronectin (FN1) gene provides protection by limiting the buildup of fibronectin in the blood-brain barrier.

In high-risk carriers, excessive fibronectin accumulation can damage the blood-brain barrier, which is responsible for removing toxic substances from the brain. The study provides evidence that blocking this damaging process could lead to new drug developments. This research moves from a previously observed genetic clue to a specific disease mechanism.

Alzheimer’s disease is characterized by progressive cognitive decline, affecting memory, language, and reasoning, alongside behavioral changes such as anxiety, depression, or social withdrawal. As the disease advances, patients may struggle with daily activities and experience significant changes in mood and cognition.